Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published ...
Apr 12, 2018
0
2
Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian ...
Mar 27, 2018
0
3
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...
Mar 21, 2018
0
16
A new study conducted by researchers at The Wistar Institute revealed how a key protein residing in the endoplasmic reticulum (ER) helps cells respond to stress. This process is especially important for B cells to respond ...
Mar 6, 2018
0
4
Scientists at The Wistar Institute have found a novel mechanism through which mutant p53 enhances metastasis by controlling tumor metabolism. The research, published online in Genes & Development, also revealed how this process ...
Feb 26, 2018
0
3
New research led by The Wistar Institute, in collaboration with Sun Yat-sen University in China, has characterized the transitory presence of myeloid-derived suppressor cells (MDSCs) in mouse and human newborns, revealing ...
Jan 15, 2018
0
98
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers ...
Dec 19, 2017
0
7
A new study from The Wistar Institute revealed the mechanism implicated in the defective function of tumor-associated dendritic cells (DCs), a specialized type of immune cells that expose the antigens on their surface to ...
Dec 14, 2017
0
4
Researchers from The Wistar Institute discovered a novel form of crosstalk among tumor cells and other cell types in the tumor microenvironment, elucidating the mechanism of action of an immunotherapeutic strategy that inhibits ...
Nov 13, 2017
0
2
A new generation DNA-based Zika vaccine demonstrated both safety and ability to elicit an immune response against Zika in humans in a phase 1 clinical trial conducted through a partnership among the Perelman School of Medicine ...
Oct 4, 2017
0
27
